CVRx, Inc. (CVRX) Earnings Call Transcript & Summary
May 11, 2026
Earnings Call Speaker Segments
Mike Vallie
executiveGood afternoon, everyone, and thanks for being with us on this CVRx First Quarter 2026 Earnings Conference Call. On the line with me today are Kevin Hykes, our President and Chief Executive Officer, and Jared Oasheim, our Chief Financial Officer. During today's remarks, we will make forward-looking statements, among them statements regarding financial guidance. Such statements rest on plans and expectations held as of today, and those may shift as time goes on. Furthermore, actual results might differ materially owing to various risks and uncertainties, such as those laid out in the earnings release published before this call and in the filings CVRx makes with the SEC. At this point, I'd like to hand the call over to Kevin Hykes, President and Chief Executive Officer of CVRx.
Kevin Hykes
executiveAppreciate it, Mike. Hello everyone, and thanks for being with us on the call for our Q1 2026 results. We kicked off 2026 on a powerful note, coming in above the top of our guidance range, powered by 22% expansion in the United States. The investments we made across 2025 are starting to show up favorably in what we're delivering. During the prior year, we focused intentionally on bolstering our sales force, sharpening how we bring our offerings to market, pushing forward key reimbursement efforts, and obtaining clearance for our pivotal clinical study. What we're seeing this quarter offers initial proof that the groundwork we've laid is now producing outcomes. Going forward through 2026, our attention stays fixed on carrying out the very same 3 strategic priorities that have steered us so far: creating a best-in-class sales force, generating deep adoption at selected centers, and steadily lowering the obstacles standing in the way of Barostim therapy uptake. Let's begin with our sales force, where the advancement we're witnessing has us encouraged. We're receiving significant contributions from a wider and more seasoned sales group, which speaks to the caliber of people we've managed to bring aboard, the rigor we've applied to how we onboard and train them, and the program-centric selling method the team grows more adept at carrying out. Throughout the quarter, we kept growing both the number of centers actively implanting and the size of our territory reach, and we intend to sustain that pace of growth for the rest of the year. Priority number two involves generating deep adoption at the centers we've chosen to target. Our program-centric playbook stresses deliberate targeting, assembling a redundant web of clinical and administrative stakeholders, and creating a well-defined Barostim workflow. At the accounts where every one of these pieces is present, we observe Barostim turning into a regular part of how heart failure gets managed instead of something considered only occasionally, which yields greater utilization; this continues to be the bedrock of our business's long-term growth. Priority number three is our ongoing effort to tackle the 3 core obstacles blocking adoption of Barostim therapy: patient access, therapy awareness, and clinical evidence. We advanced meaningfully on each of those 3 fronts during Q1. Turning first to patient access, the shift to Category I CPT codes, effective January 1, stands as the biggest reimbursement leap forward in our company's history, and its effects are already starting to appear. For submissions handled by our internal market access group, our 30-day Medicare Advantage prior authorization approval rate reached 46% in the first quarter of 2026, up against 31% in 2024 and 44% in 2025. During that quarter, our approval rate hit 50% across the first 2 months before slipping in March. Although the underlying year-over-year gain connected to the new Category I code leaves us optimistic, the softening in March mirrors the effect of concurrent shifts in the wider reimbursement landscape that are weighing on our company and on others throughout the medical device sector. Starting on January 1, fresh rules mandate that Medicare Advantage insurers give a decision on a prior authorization request in either 3 or 7 days, based on how urgent the case is, whereas the old requirement was 14 days. Consequently, some payers rolled out new automated review procedures starting in late February to cope with these tighter turnaround demands. That has led to more initial denials, especially during March, tied to an experimental designation, even for treatments that have long-standing Category I codes and solid clinical evidence. It's important to note that this doesn't reflect any shift in the clinical or coverage reasoning behind Barostim; rather, it's a fresh administrative pattern appearing widely throughout the device sector, and it isn't specific to our therapy. We see this as merely a matter of timing rather than a modification to eventual approval rates, since our market access group, when it contests these rulings with extra clinical paperwork, gets the vast majority of those early denials reversed. Although the fundamental coverage stance for Barostim has never been more robust, we aim to adjust to this evolving landscape and make certain each submission withstands the heightened administrative examination upfront. Our market access group is putting this strategy into practice with patients and providers via our internal prior authorization service, and by assisting physician offices with their own prior authorization work, so they can properly handle this shifting situation. We think the longer-term path for patient access stays very favorable, and we anticipate these payer procedures will keep settling down as the sector adapts to the updated regulatory structure. Turning to therapy awareness, we kept growing our medical education initiatives in the quarter, with special attention on the advanced practice providers who look after the majority of our indicated heart failure patients in the community. We also maintained a significant presence at a number of key cardiology conferences in the quarter, such as several presentations at the THT and ACC gatherings that showcase the expanding clinical evidence backing Barostim. Such interactions keep generating considerable enthusiasm for Barostim therapy among the clinicians who are ideally suited to spot treatment candidates. Also, just after the first quarter, we ran a trial educational symposium centered on nurses in community cardiology practices, broadening our reach past advanced practice providers to the registered nurse coordinators who likewise have a vital role in caring for heart failure patients in the community. Regarding clinical evidence, the just-launched BENEFIT-HF trial is a pivotal randomized controlled trial assessing Barostim in a wider group of heart failure patients with ejection fractions reaching 50% and NT-proBNP levels reaching 5,000. Should it succeed, this trial would grow our prevalence-based addressable market from roughly 339,000 patients at present to beyond 980,000 patients, essentially tripling our market opportunity to about $30 billion. I'm happy to report that we switched on the first site for our BENEFIT-HF trial during the first quarter and enrolled our initial patient last week. What we've heard back from those in the heart failure field regarding how rigorous and extensive the trial's design is has been quite favorable. In addition to what the trial aims to achieve clinically, we're noticing substantial involvement from sites that are working with us for the first time as a result of BENEFIT-HF, and we think this will help drive greater awareness and visibility for Barostim therapy. In closing, positive momentum is evident in all areas of our business during the first quarter. Our sales force is delivering, reimbursement conditions are getting better, and our clinical evidence program is moving forward as planned. Our attention stays on carrying out our plans for the rest of 2026, and we feel good about what lies ahead. At this point, I'd like to hand the call over to Jared for a review of the financials.
Jared Oasheim
executiveThanks, Kevin. A quick note before we start: any time I talk about year-over-year figures, I'm comparing the three months that closed on March 31, 2026 against the same stretch ending March 31, 2025, unless I say something different. Looking at Q1, our total revenue reached $14.8 million. That's a $2.4 million improvement, which works out to 20%. On the U.S. side, we booked $13.7 million, an increase of $2.5 million, or 22%. For U.S. revenue units, the counts were 429 and 359 across the periods ending March 31, 2026 and 2025. What's driving those numbers is largely the continued build-out of our U.S. Heart Failure business — we're adding new sales territories and new accounts, and we're seeing more physicians and patients become aware of Barostim. When the quarter closed, we had 257 active implanting centers altogether, which compares with 252 on December 31, 2025. As of the end of the quarter, the U.S. had 56 sales territories; that figure was 53 when 2025 ended and 45 on March 31, 2025. Revenue from Europe came to $1.1 million, a decline of $27,000, or 2%. In Europe, total revenue units dropped to 56, compared with 59 during the same period last year. The number of sales territories in Europe was unchanged at 5. For the 3 months ended March 31, 2026, gross profit was $12.9 million, an increase of $2.6 million, or 25%. Gross margin climbed to 87%, versus 84% a year earlier. A better gross margin came from two things: the typical price we got per unit went up, while what we paid to make each one went down — mostly because our manufacturing got more efficient. On the R&D side, spending reached $3.1 million, which is $0.6 million more than the same period last year, a 23% increase. What drove that? More spent on consultants, more on compensation, and more on noncash stock-based compensation, though those increases were partially balanced out by reduced spending on clinical trials. Turning to SG&A, it hit $22 million, up $0.7 million, or 3%, compared with the prior year period. The main culprits there were greater compensation costs and noncash stock-based compensation costs, partially offset by declines in consulting and advertising spending. Finally, interest expense went up by $94,000, reaching $1.6 million relative to a year ago. That gain resulted from taking on more debt through our term loan arrangement with Innovatus Capital Partners. When it came to other income on a net basis, we recorded $0.6 million, down from $1.1 million; both figures represented interest earned on our accounts that bear interest. This decrease stemmed primarily from having less cash on hand. For the first quarter of 2026, our net loss totaled $13.1 million, which works out to $0.50 per share, compared with a net loss of $13.8 million, or $0.53 per share, during the first quarter of 2025. The per-share net loss figures were calculated using 26.4 million weighted average shares outstanding in the first quarter of 2026 and 25.9 million weighted average shares outstanding in the first quarter of 2025. At the close of March 31, 2026, our cash and cash equivalents stood at $72.3 million. During the 3 months that ended March 31, 2026, net cash used in operating and investing activities was $12.3 million, versus $12.9 million across the 3 months that ended March 31, 2025. Let's turn now to guidance. Looking at the full year of 2026, total revenue is still expected to fall somewhere between $63 million and $67 million. Our gross margin outlook for the full year now sits between 85% and 87%. As for operating expenses, our expectation continues to be a range of $103 million to $107 million. Turning to the second quarter of 2026, we anticipate total revenue will be reported somewhere between $15.1 million and $16.1 million. With that, I'll hand the call back to Kevin now for closing remarks.
Kevin Hykes
executiveThanks, Jared. Q1 marks a solid beginning to the year and bolsters our belief in what lies ahead. Our sales team is growing more capable, reimbursement conditions are getting better, and kicking off BENEFIT-HF begins a significant new phase for both this company and the heart failure patients we support. There's still plenty left to accomplish, and we stay committed to execution as we keep pushing Barostim forward on its journey to being a standard of care in treating heart failure. At this point, I'd like to take questions. Operator?
Max Kruszeski
analystThis is Max, filling in for Brandon. Kevin, I'd like to begin with a question about prior authorization. From what I gather, that March decline stemmed from some of the automation you brought up. Could you speak to how the practices you've implemented to tackle this have been performing so far? And at a broader level, what does the 2026 guidance factor in regarding possible continued headwinds there?
Kevin Hykes
executiveAbsolutely. Thanks, Max — I appreciate the question. Jared will take the guidance portion, but to begin with, as I said, what happened was an unanticipated and unintended consequence of certain new federal regulations that took effect on January 1. We noticed it initially in late February. What we observed was a rise in what you might call instant denials, frequently for, once again, experimental reasons, though really it came down to administrative holes in the prior authorizations — or signatures that were effectively absent — or, as best we can determine, they're leveraging AI to uncover any piece of missing data they can, using it as justification to deny a prior authorization request right away, which then gives them the extra time the new rules now grant them to properly evaluate. So our response has involved close collaboration, clearly, with an internal team handling this every single day. Plenty of our physicians complete these themselves, but we've started deploying our own AI tools to make sure every last T is crossed and I is dotted across these extremely long prior authorization requests, allowing us to overcome this bid to buy time, which is what we believe it amounts to. The key thing is what we're observing — and this has been confirmed by partners throughout the industry via informal channels — is a very strong overturn rate. So we view this as truly — if there's any surprise, it's that these are taking somewhat longer than we anticipated. Yet the final approval rates, in our view, will be equal to or better than the earlier chapter under Category III. So I'd call it a temporary circumstance. Everyone is navigating their way through it. But I believe it's something that ultimately won't impact the approval rates for the therapy. Jared, would you like to handle the second part of the question?
Jared Oasheim
executiveAbsolutely, glad to do that. And Max, I want to make one thing clear too — something we're monitoring very carefully is that 30-day approval rate. We only got the figure for March at the close of April, and it showed a modest dip compared with the data we'd observed for January and February. So I wanted to make that point clear. Then, on the guidance side, we genuinely had no idea how Category I would play out. Our assumption was that it would produce better or increased approval rates for the prior authorizations we support in 2026, yet we chose not to rely on that while building the 2026 guidance. So, to reach the figures included in that original guide, our assumption was that approval rates at 30 days and 60 days would stay quite steady for cases needing prior authorization support. As Kevin said during the prepared remarks, I believe, we saw 30-day approval rates of approximately 44% last year. Through Q1 so far, that figure sits at 46%, which means we're running a bit ahead on a year-to-date basis. Should that trend hold, we ought not to face any problems when it comes to achieving the guide we originally put forward. One more thing, though — as Kevin noted, over the longer term we continue to view this as simply a matter of timing. For these Category I cases, we do anticipate a higher approval rate on appeals as the documentation gets refined. So our expectation remains that these prior authorizations under Category I will ultimately see a higher final, or terminal, approval rate — but we won't factor that into guidance until we actually observe it working through, or playing out.
Max Kruszeski
analystThat's useful. As a quick follow-up, congratulations on getting the first patient enrolled in BENEFIT-HF. How should we view the way that will advance over the course of the year? And Kevin, I think during your prepared remarks you said it was assisting you in getting a foot in the door with certain new centers that might not have known about Barostim. Could you discuss that specific dynamic, and then more broadly, how ought we to think about the trial's ramp across the remainder of the year?
Kevin Hykes
executiveSure. Perhaps I'll take the second part first and let Jared handle your opening question. As we've said, this is a landmark trial in heart failure. For our company it's a landmark trial, the biggest therapeutic device trial ever conducted, as far as we believe; and there are essentially 2 ways to look at it. When you consider the obstacles to adoption of the therapy, which are awareness, evidence and patient access, this trial addresses all 3 of those, and it has generated substantial awareness for us. It will serve as a foundational piece of our long-term evidence portfolio. And third, the Category B designation in effect establishes a national coverage decision for patients who enroll in this trial. That population is 3x larger than the one we currently have; so in terms of helping us further lower barriers, it ticks all 3 boxes. On a more practical note, it truly is for those ultra-conservative centers that maybe haven't yet been prepared to adopt Barostim. It's a superb engagement tool, and a lot of them are, in fact, willing to implant Barostim under the umbrella of a trial such as this. For those who have already adopted Barostim, it's an equally compelling engagement tool since it lets them treat far, far more patients, frequently patients they turn away for Barostim today. So I believe there are quite a few different tailwinds. We haven't necessarily incorporated those into our data yet. But we think, and have already observed evidence, that this is viewed as a leadership confidence boosting signal from the company and a project many of our physicians wish to be part of.
Jared Oasheim
executiveYes. And Max, regarding the question about how quickly things will ramp up. So it's genuinely encouraging for us to watch those initial sites go live and see that very first patient join the study this early in the year; even so, we're still inclined to stay somewhat conservative about what we allow ourselves to build into our 2026 expectations. What that means is we need to gain a bit more familiarity with how our site activation process works before we begin projecting how many additional sites might come online every month, and consequently, what that total looks like by the time this year ends. So our thinking is shifting toward viewing this across several quarters, perhaps even spanning a number of years, before every one of these sites is operational; reaching that goal of 150 sites activated and truly beginning to enroll patients in this trial could require anywhere from 12 to 24 months.
John Young
analystKevin and Jared, nice work on this quarter. My first question concerns why you repeated the revenue outlook. You posted a strong beat in Q1. Is that repeat simply caution regarding the first quarter? Or, as we speak here in May, are you noticing anything other than the reimbursement factors you already called out?
Jared Oasheim
executiveSure, glad to field that, John. At this point, with 1 quarter behind us, this marks a year in which our growth rate is speeding back up following substantial team building and rebuilding of the company's ground floor across the last couple of years. From a guidance standpoint, we merely preferred not to get ahead of ourselves by refreshing the full year figure once only the first quarter had passed. We're genuinely pleased with the results, since that reacceleration has returned us to 20% growth. Even so, we'd rather not jump the gun by revising guidance too soon within the year.
John Young
analystGreat. And I also want to briefly ask about the MA prior authorizations. When they approach 50%, could you remind us once more about how willing MA payers are to establish policies? And could you also remind us again, is prior authorization needed for patients enrolled in BENEFIT-HF?
Kevin Hykes
executiveSure. Thanks, John; I'll answer the second one first. The short answer is no, we don't, which clearly is an advantage. So patients who qualify and are enrolled in the trial will be handled nearly the same as traditional Medicare patients. No prior authorization needed. So that's a positive. As for the first question, can you remind me?
Jared Oasheim
executiveYes. If you get greater than a 50%...
Kevin Hykes
executiveRight. Actually, John, how this operates — we've kind of characterized it as a grinding battle of attrition. In practice, only about 10% of denials ever get appealed at all. And among those that do get appealed, across the board, more than 80% end up being approved. So the real point is: you can't quit, and you have to be persistent in how you fight every single denial. As for that figure we cited — if you take it all the way through to the administrative law judge review at the end — what the industry data indicates is that once payers start losing even fewer than half of those cases, in the high 40 percent range, they'll start granting approval rather than letting it reach an ALJ, since that ALJ step is costly and the expense falls on them. So that's probably the figure you have in mind. From what we understand, it's roughly 48%.
John Young
analystAnd as a quick follow-up to what you just said, do you have any sense on your side regarding when that figure might be within reach?
Kevin Hykes
executiveWe're beginning to observe — with quite a few payers, we're already around that level. And I suppose I left one piece of your question unanswered. As soon as you get past that point, you then ideally reach a stage where silent coverage is frequently what you have. In other words, no written policy exists yet, yet approval is in fact happening. Later on, you eventually progress to a formal coverage policy by way of several distinct routes; so that remains a few years off, but what we're witnessing as we work through this process makes us happy, and we're also happy about how many of these administrative law appeals end up going our way.
Samantha Munoz
analystSam here, filling in for Matt. So, to start, I'd like to address the ASP we saw this quarter, which came in quite strong — somewhat unusual compared to typical seasonal patterns, since Q1 usually brings a decline. Could you share what you're anticipating for ASP over the remainder of the year? And does the Cat I Code play into this? Any additional information would be appreciated.
Jared Oasheim
executiveSure, glad to address that, Sam. For the U.S. business in Q1, we posted ASPs near $32,000 — another good improvement over the 2025 average, which was nearer $31,500. At this moment, I remain somewhat hesitant to incorporate that into our guidance across 2026, roughly anticipating that figure landing near $31,000, perhaps $31,500, for the full year. That said, we're giving the sales team incentives to pursue the highest ASP they can achieve. So they'll keep working at it, and that figure could rise as time goes on — we're just not factoring it into our '26 outlook.
Samantha Munoz
analystAll right, that's useful. Then, if we return to BENEFIT-HF, what's your estimate for how long enrollment in this study will take? Also, do you have any views on when the TAM might eventually triple?
Jared Oasheim
executiveYeah, fair question. When we described this study, we mentioned a 5-to-7-year time line, since after the trial is completely enrolled, that last patient will need a 2-year follow-up period. So assuming we land around the midpoint of that range, enrolling the 2,500 patients would require roughly 4 years. After that, another 2 years would be needed to follow them. That means 6 years starting from the trial's launch this year, extending into the early 2030s, before an FDA approval could potentially be seen.
Frank Takkinen
analystI'd like to kick things off by discussing a few of the sites with stronger utilization. From what I recall, you mentioned before that the top 20% of sites were averaging roughly 1.5 procedures each month. Could you give us an update on that top 20% group and what their utilization rates currently look like? Also, any thoughts on the flip side of that — are more sites moving up into that 1.5 per month level?
Jared Oasheim
executiveSure. Thanks for asking, Frank. We wanted to establish a clear benchmark for investors and those outside the company so they could grasp what these centers are capable of. So in the fourth quarter, we ran that as an ad hoc analysis on our top 20% of centers, and it showed they were each performing more than 1 patient per month, which illustrates the potential of these centers as we keep expanding our programs. I don't expect we'll report this as a quarterly metric, since we recognize there's seasonality involved when we look at results from Q4 heading into Q1. That said, perhaps annually, we could look back at how many additional centers have now crossed that threshold of reaching 1 patient a month. So maybe we'll provide a refresh on that figure in Q4 of this year.
Frank Takkinen
analystAlright, that's reasonable. Then let me attempt a different question you might not want to tackle — could you possibly discuss prior auth rates for April? If we saw 50% across the first 2 months and finished at 46%, my read is that March was likely in the high 30s. I'm just wondering whether that prior auth rate moved up or down from there.
Jared Oasheim
executiveYeah. Frank, I wouldn't say March was that severe. Part of it comes down to the volume of prior auths getting processed during March versus January and February. A bolus arrived during January, which pushed that rate somewhat higher. Regarding April, though, it does appear to be recovering. That said, we still lack 30-day rates for April. At this moment, what we have is roughly 11 days' worth of data covering all prior authorizations submitted during April. From those early rates, we're noticing some recovery, landing nearer the approval rates from January and February rather than what March showed. So once more, we anticipate some fluctuation as we roll out new tools and other payers roll out new tools in response to this new regulatory — regulation introduced at the start of the year. Still, in the early April data, we are observing a modest recovery.
Chase Knickerbocker
analystPerhaps I could just ask a follow-up about a few of the moving parts with Medicare Advantage. Would you mind reminding us how Part B and Medicare Advantage break down inside your Medicare segment?
Jared Oasheim
executiveI believe that's one I can handle, Frank. Oh, wait — the traditional, sorry, Chase, my apologies. Roughly 1/3 of the patients we serve overall are traditional Medicare. Another 1/3 are Medicare Advantage. Private payers, VA, and possibly patients without coverage make up the last 1/3 of that patient population. That means Medicare covers 2/3, though it's divided 50 to 50 between traditional Medicare and Medicare Advantage.
Chase Knickerbocker
analystAnd is that consistent with the mix of business you have right now?
Jared Oasheim
executiveYeah. Yeah. We're pretty much right where we'd expect, maybe even slightly more tilted toward those Medicare members.
Chase Knickerbocker
analystUnderstood. And to build on what Frank asked. Your outlook bakes in roughly the same approval rate you observed in '25. Could you talk about how at ease you are with that? Is it what you saw in April, in terms of that rate recovering in March? Or did it truly have no effect on revenue trajectory in March? Maybe just address how comfortable you are with that trend.
Jared Oasheim
executiveYeah. Yeah; it's the second one, Chase. Yeah, we feel good about the top-line guidance we gave. We've reached a place where we think MA approval rates at 30 days, or even the terminal rates, will match or exceed what we saw in 2025. But we'd like to watch this unfold a bit more before we'd narrow the range on the guidance.
Chase Knickerbocker
analystUnderstood. That's my final question. With July nearly here and the OPPS proposed rule on our minds, has there been anything noteworthy in terms of discussions — is there anything you're able to tell us regarding talks about where your APC sits, or any other perspective you folks might have on that?
Kevin Hykes
executiveAbsolutely. Appreciate it, Chase. That's mine to answer. Feels like we're back in Groundhog Day once more, I suppose. The positive side is that, just like in previous years, we've been at this since January, engaging with CMS in a very productive way. The data we have now beats anything we've had before, and that goes for the pooled data from this group of 5 companies too. What matters is that this time around, every one of those 5 companies begins at 1580, something that hasn't happened previously. So our feeling is that this sets us up well for the current cycle, and we're holding out hope that this is finally the year we can close the book on this matter. That said, there's nothing concrete at this point, and naturally no promises from CMS, though the level of engagement has been tremendous.
K. Gong
analystAllen here, filling in for Robbie. I've got one quick question regarding what you anticipate for center additions during this year. My understanding is that you'd earlier mentioned an average of, let's say, high single-digit centers each quarter. Compared with what we were expecting, the first quarter seemed somewhat on the lower end. That said, I was interested in what you said about the trials possibly drawing in new centers that had not been CVRx customers in the past. Given that the onboarding process for such centers takes longer, how should we frame that high single-digit expectation? Might there be some potential upward pressure, since some of these newer accounts are coming in via the trials instead of, perhaps, your standard base commercial efforts?
Jared Oasheim
executiveAllen, glad to field that. Thank you. Our expectation, then, is that the great majority of centers activated in BENEFIT-HF will already have experience with Barostim. So we don't think this will be a meaningful driver for new center additions in the near term. Down the road, once we bring on some of those new centers and they begin treating patients, they'll be counted in the active implanting center totals; but my sense is that won't move the needle across the coming few quarters through 2026. On what to expect for new center additions each quarter, we're still putting forward the expectation of high single digits on a net basis from one quarter to the next, though there could be some variability, as happened in the first quarter when we were plus 5 here in Q1. So one quarter might reach low double digits. In other quarters, we're sitting at roughly 5 or 6 new center additions per quarter.
K. Gong
analystUnderstood. Now, as a brief second question regarding what's happening with Medicare Advantage: given that your market access group has to challenge these rulings, and considering the operating expense guidance you repeated, might there be a need — could this include possibly growing that group so it can deal with a greater volume of denials, perhaps spending somewhat more to keep pressing forward while simultaneously handling those denials? Or do you feel that's not — something your existing group can manage as it stands?
Kevin Hykes
executiveYeah. Thank you, Al; excellent question. The brief response is no. We don't. In effect, we're using AI to counter AI. Consequently, we don't think our group will become any less productive or that the load on them will shift significantly. Essentially, we're answering a fresh instrument or tactic being used against us, and we're sure we can answer suitably and that this group can keep backing prior auths at approximately the same — with the same efficiency as in the past.
Kevin Hykes
executiveThanks, operator, and I appreciate all of you being here with us today. We're grateful for your ongoing backing, and we're eager to share where things stand when we speak again in three months. Thanks so much.
Operator
operatorThat brings us to the end of today's call. At this point, you're free to hang up. We appreciate you joining us.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete CVRx, Inc. transcript — plus 133,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to CVRx, Inc. earnings transcripts and 133,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in CVRx, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.